Fig. 6

The MASTL inhibitor, MKI-2, sensitizes tumors with increased chromosomal instability and downregulation of MASTL-ENSA-Aurora A. A Schematic representation of MKI-2 treatment schedules and tumor volume tracking results. Representative images and quantification of tumor volume of the 4T1-luc syngeneic mouse model treated with vehicle (n = 7) or MKI-2 (n = 7) for 18 d. B Quantification of p-H3 and cleaved caspase 3 intensities (left panel). Tumor tissues were stained with the indicated antibodies (right panel). Scale bar, 20 μm. The means of values from three separate experiments are shown. Error bars indicate standard deviation (SD). The data represent typical results and are presented as the mean ± SD of values from three independent experiments. C The nuclear size/diameter was measured using computer-assisted image analysis (AxioVision software 4). Nuclear sizes were plotted following computer-assisted imaging analysis of 300 nuclei randomly selected from each group. Error bars indicate SD. The data represent typical results and are presented as the mean ± SD of values from three independent experiments; ****p < 0.0001. Scale bar, 20 μm. D Quantification of p-ENSA and p-Aurora A intensities (left panel). Tumor tissues were stained using the indicated antibodies (right panel). Scale bar, 20 μm. The means of values from three separate experiments are shown. Error bars indicate SD. The data represent typical results and are presented as the mean ± SD of values from three independent experiments